Study title:
Sullivan-M-P, Fuller-L-M, Chen-T, Fisher-R, Fryer-C, Gehan-E,Gilchrist-G-S, Hays-D, Hanson-W, Heller-R, Higgins-G, Jenkin-D, Kung-F, Sheehan-W, Tefft-M, Ternberg-J, Wharam-M.
Intergroup Hodgkin's disease in children study of stages I and II: a preliminary report.
Cancer treatment reports, {Cancer-Treat-Rep}, Apr 1982, vol. 66, no. 4, p. 937-47, ISSN: 0361-5960.Sullivan-M-P, Fuller-L-M, Chen-T, Fisher-R, Fryer-C, Gehan-E,Gilchrist-G-S, Hays-D, Hanson-W, Heller-R, Higgins-G, Jenkin-D, Kung-F, Sheehan-W, Tefft-M, Ternberg-J, Wharam-M.
Intergroup Hodgkin's disease in children study of stages I and II: a preliminary report.
Cancer treatment reports, {Cancer-Treat-Rep}, Apr 1982, vol. 66, no. 4, p. 937-47, ISSN: 0361-5960.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Neoplasms [C04]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: PROCARBAZINE |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|